Sanofi and CD&R have signed a share purchase agreement for the sale of a 50% stake in the consumer health business.

The company's molecular research and drug-development platform taps what it calls nature's wisdom to drive the discovery of ...

Sanofi's deep partnership with OpenAI could be a huge differentiating factor. Check out why I rate SNY stock a buy.

Emanuele de Rinaldis, global head of precision medicine and computational biology at Sanofi, commented: “[O]ur drug discovery strategy is driven by precision medicine. We seek to describe ...

further supporting the potential our medicine has to improve outcomes for patients struggling with relapsed multiple myeloma,” he added. Sanofi says it will file to extend the label for Sarclisa ...

The pharma signed an agreement handing PE firm CD&R a 50% stake in its Capella unit. Elsewhere, Gilead and Ultragenyx secured ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been accepted for priority review by the US Food and Drug Administration (FDA ...

Regeneron and Sanofi said an FDA green light would make Dupixent the first targeted medicine in the U.S. for bullous pemphigoid, a debilitating and relapsing skin disease with underlying type 2 ...

Kuehne+Nagel supports Sanofi in multiple countries worldwide, including Hungary, the UK, and the UAE, by providing customised ...

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the FDA has accepted ... If approved, Dupixent would be the first and only targeted medicine to treat bullous pemphigoid (BP) in the ...

relief medicine Buscopan (hyoscine butylbromide), among others. Sales in the business totalled €5.6bn ($5.8bn) in 2023, accounting for 11% of Sanofi’s total business. Sanofi also claims Opella ...

Regeneron and Sanofi said an FDA green light would make Dupixent the first targeted medicine in the U.S. for bullous pemphigoid, a debilitating and relapsing skin disease with underlying type 2 ...